Andere talen Redwood Pharma AB

Aandelen

REDW

SE0021512134

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:07:55 17-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,035 ^SEK	-0,48%		-5,48%	-77,98%

08/05	Redwood Pharma AB (publ)'s product RP501 trok veel belangstelling op ARVO in Seattle	CI
07/05	Twee internationale bedrijven beginnen due diligence op het product RP501 van Redwood Pharma AB (publ) in de aanloop naar mogelijke commerciële overeenkomsten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle	08/05
Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	08/05
Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements	07/05
Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	07/05
Redwood Pharma's board subscribes to units in the ongoing new issue	06/05
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04
Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle	28/02
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02
Redwood Pharma's CEO Martin Vidaeus in year-end interview	20/12
Redwood Pharma to participate in the JP Morgan Healthcare Conference	19/12
Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)	30/11
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23/11
Redwood Pharma to participate in the NLS Days partner conference in Copenhagen	22/11
Redwood Pharma to participate in the BIO-Europe partnering conference in Munich	19-10-23
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07-08-23
Redwood Pharma presents positive results from a clinical study with RP501 against dry eye	31-05-23
Redwood Pharma AB Presents Positive Results from Clinical Study with RP501 Against Dry Eye	31-05-23
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09-05-23
Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye	17-03-23
Redwood Pharma AB Completes Recruitment for Clinical Trial with RP501 for Dry Eye	17-03-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Redwood Pharma AB

Aandelen

REDW

SE0021512134

Andere talen

Filters